1. Medtech Insight

Three Candidates In Running To Become FDA Commissioner, Including Acting Chief Ned Sharpless

 
• By Sue Darcey

The Trump administration is seriously considering three candidates to become US Food and Drug Administration commissioner when the legally mandated 210-day term of acting commissioner Norman “Ned” Sharpless ends on 4 November.

candidates in the running to become permanent FDA commissioner when the acting commissioner’s term ends Nov. 4
• Source: M.D. Anderson Cancer Center (Hahn photo); Harvard University Medical Faculty (Kimball photo); file photo (Sharpless photo)

While four former FDA commissioners on 3 September endorsed Ned Sharpless, the agency’s acting commissioner, to be the Trump administration’s permanent choice to lead the agency, an M.D. Anderson Cancer Center oncologist or Harvard University dermatologist may also be chosen.

Besides Sharpless, the other two candidates being considered to lead FDA are Harvard University dermatology professor Alexa Boer Kimball and M.D. Anderson Cancer Center radiation oncologist Stephen Hahn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.